Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1993-09-29
1995-09-12
Warden, Jill
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 21, A61K 3800
Patent
active
054496713
ABSTRACT:
The intraocular use of TGF-.beta..sub.3 in connection with glaucoma filtration surgery is described. A composition containing TGF-.beta..sub.3 is applied to the surgical site to suppress the production and/or alter the composition of extracellular matrix synthesized by fibroblasts at the surgical site, and thereby reduce the formation of scar tissue and consequent impairment of the outflow of aqueous humor through a fistula created during the surgery.
REFERENCES:
patent: 5057494 (1991-10-01), Sheffield
patent: 5108989 (1992-04-01), Amento et al.
patent: 5124392 (1992-06-01), Robertson
Cheifelz et al, "Distinct Transforming Growth Factor-.beta. . . . to Three TGF-.beta. Isoforms", J. Biological Chem., vol. 265 No. 33, pp. 20533 (1990).
Ferguson, W. F. "Wound Healing, Scarring and TGF-.beta. Isoforms", Abstract, Conference on TGF-.beta.s: Biological and Clinical Applications, May 4-6, 1994, NIH, Bethesda, Md.
Tahery, M. M., et al., "Pharmacologic Control of Wound Healing in Glaucoma Filtration Surgery", Journal of Ocular Pharmacology, vol. 5, No. 2, pp. 155-179 (1989).
Tripathi, R. C., "Growth Factors in the Aqueous Humor and Their Therapeutic Implications in Glaucoma and Anterior Segment Disorders of the Human Eye", Drug Development Research, vol. 22, pp. 1-23 (1991).
Costa, V. P., et al, "Wound Healing Modulation in Glaucoma Filtration Surgery", Opthalmic Surgery, ; vol. 24, No. 3, pp. 152-170 (Mar. 1993).
Textbook of Glaucoma (2nd ed.), ed. M. Bruce Shields, M.D., "Glaucoma Filtering Procedures", Chapter 34, pp. 461-487, Baltimore, Md.: Williams & Wilkins (1987).
Derynck, R., et al., "A new type of transforming growth factor-.beta., TGF-.beta..sub.3 ", EMBO Journal, vol. 7, NO. 12, pp. 3737-3743 (1988).
Connor Jr., T. B., et al., "Correlation of Fibrosis and Transforming Growth Factor-.beta. Type 2 Levels in the Eye", The American Society for Clinical Investigation, Inc., vol. 83, pp. 1661-1666 (May 1989).
ten Dijke, P., et al., "Identification of another member of the transforming growth factor type .beta. gene family", Proc. Natl. Acad. Sci. USA, vol. 85, pp. 4715-4719 (Jul. 1988).
Levine, et al., American Journal Pathol., vol. 143, pp. 368-380 (1993).
Smiddy, W., et al., "Transforming Growth Factor Beta", Archives of Ophthalmology, vol. 107, No. 1, pp. 577-580 (1989).
Glaser, B., et al., "Transforming Growth Factor-.beta..sub.2 for the Treatment of Full-thickness Mascular Holes", Ophthalmology, vol. 99, No. 7, pp. 1162-1178 (1992).
Glaser, B., et al., "Induction of a `Retinal Patch` By Transforming Growth Factor-Beta in the Treatment of Full Thickness Macular Holes", Investigative Ophthalmology & Visual Science, vol. 32, No. 4, p. 713 (Mar. 1991).
S. J. Ryan Chief Editor, "Retina", Chapter 68, published 1989 by the C. V. Mosby Company (St. Louis), pp. 229-242.
Nixon Jon C.
York Billie M.
Alcon Laboratories Inc.
Arno James A.
Brown Gregg C.
Touzeau Plynn
Warden Jill
LandOfFree
Use of TGF-.beta.3, to prevent or retard fistula closure followi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of TGF-.beta.3, to prevent or retard fistula closure followi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of TGF-.beta.3, to prevent or retard fistula closure followi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-405409